Abstract
Ovarian cancer is an extremely aggressive disease in which the vast majority of patients face a very poor prognosis. Although most patients initially respond to current chemotherapeutic regimens that include a combination of platinum- based therapy (cisplatin/carboplatin) and paclitaxel, the vast majority of them quickly relapse and develop increased resistance to available treatments. Thus, intrinsic and acquired chemotherapy resistance is a major obstacle in the treatment of ovarian cancer patients. Consequently, the priorities for basic and translational ovarian cancer research need to include the identification of novel therapies directed against key molecular targets and signaling pathways in platinum resistant disease. At the same time, we need to develop novel systems for drug delivery aimed at increasing the efficacy and reducing the toxicity of platinum-based treatments. Improving the current responses to platinum chemotherapy is critical not only for achieving a better outcome clinically, including a longer survival, but also for allowing patients to have a better quality of life while in treatment.
Keywords: Combination therapy, CSC pathways, nanotechnology based platforms, oncomap and tumor sequencing, ovarian cancer stem cell markers, platinum resistance.
Current Medicinal Chemistry
Title:Targeting Platinum Resistant Disease in Ovarian Cancer
Volume: 21 Issue: 26
Author(s): S.L. Morgan, J.E. Medina, M.M. Taylor and D.M. Dinulescu
Affiliation:
Keywords: Combination therapy, CSC pathways, nanotechnology based platforms, oncomap and tumor sequencing, ovarian cancer stem cell markers, platinum resistance.
Abstract: Ovarian cancer is an extremely aggressive disease in which the vast majority of patients face a very poor prognosis. Although most patients initially respond to current chemotherapeutic regimens that include a combination of platinum- based therapy (cisplatin/carboplatin) and paclitaxel, the vast majority of them quickly relapse and develop increased resistance to available treatments. Thus, intrinsic and acquired chemotherapy resistance is a major obstacle in the treatment of ovarian cancer patients. Consequently, the priorities for basic and translational ovarian cancer research need to include the identification of novel therapies directed against key molecular targets and signaling pathways in platinum resistant disease. At the same time, we need to develop novel systems for drug delivery aimed at increasing the efficacy and reducing the toxicity of platinum-based treatments. Improving the current responses to platinum chemotherapy is critical not only for achieving a better outcome clinically, including a longer survival, but also for allowing patients to have a better quality of life while in treatment.
Export Options
About this article
Cite this article as:
Morgan S.L., Medina J.E., Taylor M.M. and Dinulescu D.M., Targeting Platinum Resistant Disease in Ovarian Cancer, Current Medicinal Chemistry 2014; 21 (26) . https://dx.doi.org/10.2174/0929867321666140414102701
DOI https://dx.doi.org/10.2174/0929867321666140414102701 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology Liposomes: Targeted and Controlled Delivery System
Drug Delivery Letters Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry Ceramic Nanoparticles: Fabrication Methods and Applications in Drug Delivery
Current Pharmaceutical Design Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology Natural Compounds Containing a Condensed Cyclopropane Ring. Natural and Synthetic Aspects
Current Organic Chemistry The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Current Cancer Drug Targets The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 3dswap-pred: Prediction of 3D Domain Swapping from Protein Sequence Using Random Forest Approach
Protein & Peptide Letters Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Momordicacharantia: A New Strategic Vision to Improve the Therapy of Endoplasmic Reticulum Stress
Current Pharmaceutical Design Novel Targets of Vitamin D Activity in Bone: Action of the Vitamin D Receptor in Osteoblasts, Osteocytes and Osteoclasts
Current Drug Targets Recent Studies and Biological Aspects of Substantial Indole Derivatives with Anti-cancer Activity
Current Organic Chemistry Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in ApcMin/+ Mice
Current Cancer Drug Targets